Skip to content
Menu
Find Partners
Ion Channel World Map
Companies
Labs
Nonprofits
Resources
Ion Channel Overview
Fundamentals
Ion Channel Drugs
Interviews
Analytics
Expert opinions
Books
Infographics
Journal Covers
Quotes
External Resources
Blog
Menu
Find Partners
Ion Channel World Map
Companies
Labs
Nonprofits
Resources
Ion Channel Overview
Fundamentals
Ion Channel Drugs
Interviews
Analytics
Expert opinions
Books
Infographics
Journal Covers
Quotes
External Resources
Blog
Industry
-
02/08/2022
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of its TRPM8 agonist AR-15512 for the Treatment of Dry Eye Disease
Source: Aerie Pharmaceuticals
Industry
-
30/06/2022
Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist
Source: Axalbion
Industry
-
25/05/2022
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
Source: Aerie Pharmaceuticals
Industry
-
21/10/2021
Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist
Source: Axalbion
Industry
-
30/04/2021
Aerie Pharmaceuticals completes enrollment of its Phase 2b clinical trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease
Source: Aerie Pharmaceuticals
